The current Wegovy prescribing information and current Zepbound prescribing information describe several overlapping concerns
Nausea decreases as your body adjusts to the changes from GLP-1s
Her weight has fluctuated, but she's never been obese
In Eli Lilly's Phase 2 clinical trial (published in the New England Journal of Medicine, 2023), 338 adults with obesity or overweight (without diabetes) were treated with retatrutide for 48 weeks
One focus of the recent research is into the long-term interaction of GIP and GLP-1 receptor signalling, which could potentially be clarified if a long-acting GIP receptor agonist, which has already been investigated in rodent studies [24,25], can also be studied in humans
The Retatrutide starting dose is 2 mg once weekly